European Primary Care Cardiovascular Society

U-Prevent helps to assess individual CV risk and treatment effect

10' education - July 3, 2019 - Jannick Dorresteijn, MD, PhD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

Lowering remnants becomes more important, also in light of the obesity epidemic

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard
EPCCS Annual CV Summit

New diagnostic algorithm and therapeutic options in HF management

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander
EPCCS Annual CV Summit

Update on managing CV risk in diabetes: what's the evidence?

5' education - Mar. 22, 2019 - Lisbon, Portugal - Kamlesh Khunti & Richard Hobbs
EPCCS Annual CV Summit

Stroke prevention in atrial fibrillation

5' education - Mar. 21, 2019 - Lisbon, Portugal - Michaela Machácová & Richard Hobbs
EPCCS Annual CV Summit

Recent updates to the international Hypertension Guidelines - where do they vary and what should we agree in primary care?

5' education - Mar. 21, 2019 - Lisbon, Portugal - Richard McManus & Richard Hobbs
EPCCS Annual CV Summit

Multimorbidity, CV disease and polypharmacy

10' education - Mar. 21, 2019 - Lisbon, Portugal - Dr. David Silvério Rodrigues

Lifestyle improvement forms the basis of comprehensive ACC/AHA guideline for primary prevention

3' education - Mar. 20, 2019 - New Orleans, LA, USA - Dr. Amit Khera

Implementation of advice facilitated by new overarching recommendations in ACC/AHA primary prevention guideline

3' education - Mar. 20, 2019 - New Orleans, LA, USA - Donna Arnett, MD

84% True AF in those with irregular pulse detected with smartwatch in proof-of-concept study

3' education - Mar. 20, 2019 - New Orleans, LA, USA - Michael Valentine, MD

First ischemic events and recurrent events reduced with highly purified omega-3 fatty acid

3' education - Mar. 20, 2019 - New Orleans, LA, USA - Deepak L. Bhatt, MD

ESC/ESH Guidelines on management of hypertension: what's new?

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK

EPCCS

3' education - Feb. 8, 2019

EPCCS society: what is available for members?

3' education - Feb. 7, 2019 - Prof. Richard Hobbs, MD

May Measurement Month: Get involved to increase awareness on elevated blood pressure

3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK

Primary prevention of CV events with aspirin: yes or no?

3' education - Jan. 31, 2019 - Prof. dr. Freek Verheugt - Amsterdam, The Netherlands

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

Independent association of systolic and diastolic hypertension with CV outcomes

Literature - July 23, 2019 - Flint AC et al. - N Engl J Med 2019

In a large cohort study of 1.3 million participants, both systolic and diastolic hypertension were associated with composite of MI, ischemic stroke and hemorrhagic stroke, independent of thresholds defining hypertension.

U-Prevent helps to assess individual CV risk and treatment effect

10' education - July 3, 2019 - Jannick Dorresteijn, MD, PhD
The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?

The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?

No association between vitamin D supplementation and reduction in major adverse CV events

Literature - July 2, 2019 - Barbarawi M, et al. - JAMA Cardiol 2019
In a meta-analysis of 21 RCTs including diverse populations, supplementation with vitamin D did not result in a reduction of MACE, MI, stroke/CVA, CV mortality and all-cause mortality compared to placebo.

In a meta-analysis of 21 RCTs including diverse populations, supplementation with vitamin D did not result in a reduction of MACE, MI, stroke/CVA, CV mortality and all-cause mortality compared to placebo.

Those who quit smoking after first CV event delay recurrent event and live longer

Literature - July 2, 2019 - Van den Berg MJ et al., - Am J Heart 2019

In the SMART population, smoking cessation after an event resulted in about 5 years longer survival and delay of recurrent events by about 10 years, compared to those who continue to smoke.

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD
Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.

EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD
Prof. Jacob discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.

EuroPrevent 2019 Prof. Jacobs discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.

EAPC formulates preference for CV risk prediction tool for use in clinical practice

News - June 26, 2019

The European Association of Preventive Cardiology reviewed various online risk prediction algorithms and considers advantages and caveats, and gives guidance on which tool to use for which patient.

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD
Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.

EuroPrevent 2019 Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.

Original intensive glucose control does not result in CV benefit in T2DM after 15 years: no legacy effect

Literature - June 25, 2019 - Reaven PD, et al. - N Eng J Med 2019
In a follow-up study of VADT, original intensive glucose lowing over 5.6 years did not result in improved outcomes in T2DM patients vs. standard-therapy after 15 years, providing no evidence of a legacy effect.

In a follow-up study of VADT, original intensive glucose lowing over 5.6 years did not result in improved outcomes in T2DM patients vs. standard-therapy after 15 years, providing no evidence of a legacy effect.

Lowering remnants becomes more important, also in light of the obesity epidemic

EAS 2019 - Maastricht, The Netherlands

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard
Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

Lipid-lowering drug prescription decreases with age but increases with frailty

Literature - June 18, 2019 - Kleipool EEF et al. - Age and Ageing 2019

Based on a large Dutch primary care database, lipid-lowering treatment declined with increasing age in subjects aged ≥70 years, with higher prescription in frail vs. non-frail older adults regardless of CVD at baseline.

CVD risk assessment model helps assess individual preventive treatment benefit

News - June 18, 2019

The LIFE-CVD model can assess 10-year and lifetime CVD risk and life-years gained free from CVD and the effect of interventions in apparently healthy people.